Business Context and Reporting Period
Company: AngioDynamics, Inc. (ANGIO)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended August 31, 2024 (Fiscal Q1 2025)
Business Overview: AngioDynamics designs, manufactures, and sells medical devices for vascular access, peripheral vascular disease treatment, and oncology. The company operates through two segments: Med Tech and Med Device.
Key Financial Metrics
| Metric | Q1 2025 (Aug 31, 2024) | Q1 2024 (Aug 31, 2023) |
|---|---|---|
| Net Sales | $67.5 million | $78.7 million |
| Gross Profit | $36.7 million | $40.1 million |
| Gross Margin | 54.4% | 50.9% |
| Operating Income (Loss) | $(13.1) million | $35.0 million |
| Net Income (Loss) | $(12.8) million | $45.9 million |
| Diluted EPS | $(0.31) | $1.15 |
| Cash and Equivalents | $55.0 million | $57.6 million |
| Operating Cash Flow | $(18.3) million | $(25.9) million |
| Long-Term Debt | $0 | $0 |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 14.2% year-over-year. This was primarily driven by the divestiture of the PICC, Midline, dialysis, and BioSentry businesses, as well as the discontinuation of the RadioFrequency Ablation and Syntrax product lines, which collectively reduced sales by approximately $12.0 million compared to the prior year.
- Segment Performance:
- Med Tech: Revenue increased 8.2% to $28.0 million, driven by Auryon growth, partially offset by softness in NanoKnife and thrombus management platforms.
- Med Device: Revenue decreased 25.2% to $39.5 million, largely due to the aforementioned divestitures and product discontinuations.
- Profitability Shift: The company reported a net loss of $12.8 million compared to a net income of $45.9 million in the prior year. The prior year included a one-time pre-tax gain of $47.8 million from the sale of the dialysis and BioSentry businesses, which is not present in the current period.
- Restructuring Costs: The company incurred $3.6 million in restructuring charges related to a plan announced in January 2024 to transition manufacturing to third-party providers. Total restructuring charges to date are $13.1 million.
- Legal Settlement: The company entered into a settlement agreement with Becton, Dickinson and Company (BD) regarding patent litigation, involving a one-time payment of $7.0 million and future annual minimum payments.
Guidance, Outlook, and Risks
- Liquidity: Management believes current cash balances ($55.0 million) and cash generated from operations are sufficient to meet capital needs for at least the next 12 months. The company has no outstanding debt.
- Share Repurchase: On July 16, 2024, the Board authorized a $15.0 million share repurchase program. As of August 31, 2024, $14.5 million remained available.
- Restructuring Outlook: The manufacturing restructuring plan is expected to be completed in the third quarter of fiscal year 2026, with total estimated costs between $38.5 million and $43.25 million.
- Risks and Contingencies:
- Legal Proceedings: The company is defending approximately 50 product liability claims related to port products. Outcomes are uncertain and could materially impact financial results.
- Valuation Allowance: The company maintains a valuation allowance on federal and state net operating loss carryforwards due to a lack of sustained profitability, which impacts the effective tax rate.
- Market Risks: Exposure to foreign currency fluctuations (approx. 3.4% of sales in foreign currencies) and supply chain challenges including inflation and labor shortages.
Investor Verification Checklist
- Divestiture Impact: Verify the long-term revenue trajectory of the remaining portfolio following the sale of PICC, Midline, dialysis, and BioSentry businesses.
- Restructuring Execution: Monitor the progress and total cost of the manufacturing transition to third-party providers against the estimated $38.5M–$43.25M range.
- Legal Exposure: Track the status of the ~50 port product liability claims and the financial impact of the BD settlement payments.
- Cash Burn Rate: Assess the sustainability of the $55.0 million cash position given the current operating cash outflow of $18.3 million for the quarter.
- Med Tech Growth: Evaluate the sustainability of the 8.2% growth in the Med Tech segment, specifically the performance of the Auryon platform.